Intravitreal Rituximab-Associated Retinal Occlusive Vasculitis.

PURPOSE: To describe a 90-year-old patient who was referred to a private retina specialist with gradually worsening vision and floaters in the left eye.

METHODS: A retrospective case report is presented.

RESULTS: The patient was treated with intravitreal rituximab injections for intraocular lymphoma with resulting vision loss to the level of hand motions from severe granulomatous uveitis and retinal occlusive vasculitis.

CONCLUSIONS: Retinal occlusive vasculopathy secondary to rituximab intravitreal injections is a rare clinical entity with only a single previous case reported in the literature. However, there are reports of systemic vasculitis after systemic administration of rituximab. Clinicians should be aware of the possibility of ocular hypertension, granulomatous anterior uveitis, and/or retinal occlusive vasculitis after intravitreal rituximab use. Consideration should be given to the inflammatory risk of rituximab intravitreal injections to reduce the potential for treatment-induced vision loss.